One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
Trial Details
- NCT ID
- NCT06618313
- Phase
- NA
- Sponsor
- Beijing GoBroad Hospital
- Status
- RECRUITING
- Cancer Type
- Non-Hodgkin Lymphoma Lymphoma
- Interventions
- JCXH-213,an mRNA-LNP based in vivo CAR therapy
- Locations (sample)
- Beijing, China|39.9075,116.39723
Key Eligibility Criteria
- Cytologically or histopathologically confirmed CD19-positive B-cell Hodgkin lymphoma according to WHO 2022 criteria, including but not limited to p…
- ECOG performance status 0 to 1.
- Existing measurable lesions (Lugano 2014 criteria, as detailed in Appendix 2), meeting one of the following conditions: 1) nodal lesions with a lon…
For full eligibility, visit ClinicalTrials.gov.